Zoetis Inc. (NYSE:ZTS) today announced that it has extended until Oct. 30, 2013 at 5:00 p.m., New York City time, the expiration date of its offer to exchange:
- $400,000,000 aggregate principal amount of its unregistered 1.150% Senior Notes due 2016 (the “2016 unregistered notes”) for a like principal amount of its 1.150% Senior Notes due 2016 that have been registered under the Securities Act of 1933;
- $750,000,000 aggregate principal amount of its unregistered 1.875% Senior Notes due 2018 (the “2018 unregistered notes”) for a like principal amount of its 1.875% Senior Notes due 2018 that have been registered under the Securities Act of 1933;
- $1,350,000,000 aggregate principal amount of its unregistered 3.250% Senior Notes due 2023 (the “2023 unregistered notes”) for a like principal amount of its 3.250% Senior Notes due 2023 that have been registered under the Securities Act of 1933; and
- $1,150,000,000 aggregate principal amount of its unregistered 4.700% Senior Notes due 2043 (the “2043 unregistered notes”) for a like principal amount of its 4.700% Senior Notes due 2043 that have been registered under the Securities Act of 1933.
DB Services Americas, Inc.Attention: Reorg. Department5022 Gate Parkway, Suite 200Jacksonville, FL 32256 DB.Reorg@db.comFax: 615-866-3889Information: 877-843-9767This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of an appropriate prospectus. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2012, the company generated annual revenues of $4.3 billion. With approximately 9,300 employees worldwide at the beginning of 2013, Zoetis has a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. Forward-Looking Statements: This press release contains forward-looking statements, which reflect Zoetis's current views with respect to business plans or prospects, future operating or financial performance, and other future events. These statements are not guarantees of future performance. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov , www.zoetis.com , or on request from Zoetis.